Quality and Batch-to-Batch Consistency of Original and Biosimilar Epoetin Products
- PMID: 26869417
- DOI: 10.1016/j.xphs.2015.10.019
Quality and Batch-to-Batch Consistency of Original and Biosimilar Epoetin Products
Abstract
Comprehensive physicochemical characterization and biological assays are essential parts in assessing quality attributes of biologicals. Here, we compared the quality of different marketed recombinant human erythropoietin (epoetin) products: originators, Eprex and NeoRecormon as well as 2 biosimilars, Retacrit and Binocrit. In addition, assessment of batch-to-batch variability was included by collecting 2 or more batches of each product. Common assays which included sodium dodecyl sulfate-polyacrylamide gel electrophoresis, high-performance size-exclusion chromatography, asymmetrical flow field-flow fractionation, capillary zone electrophoresis, and potency testing were used. Of the tested products and among batches of single products, variations in epoetin content, isoform profiles, and potency were found. Ultimately, this study demonstrated the high quality of epoetin products with some degree of variation among products and batches, confirming the "similar but not identical" paradigm of biologicals.
Keywords: biosimilar; immunogenicity; physicochemical properties; protein characterization; recombinant human erythropoietin.
Copyright © 2016. Published by Elsevier Inc.
Similar articles
-
Quality of original and biosimilar epoetin products.Pharm Res. 2011 Feb;28(2):386-93. doi: 10.1007/s11095-010-0288-2. Epub 2010 Oct 1. Pharm Res. 2011. PMID: 20886265 Free PMC article.
-
Comparison of the pharmacokinetic and pharmacodynamic profiles of one US-marketed and two European-marketed epoetin alfas: a randomized prospective study.Drugs R D. 2011;11(1):61-75. doi: 10.2165/11588270-000000000-00000. Drugs R D. 2011. PMID: 21410296 Free PMC article. Clinical Trial.
-
An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin.BioDrugs. 2015 Aug;29(4):285-300. doi: 10.1007/s40259-015-0136-3. BioDrugs. 2015. PMID: 26334631 Free PMC article.
-
Clinical safety of biosimilar recombinant human erythropoietins.Expert Opin Drug Saf. 2012 Sep;11(5):819-40. doi: 10.1517/14740338.2012.712681. Epub 2012 Aug 13. Expert Opin Drug Saf. 2012. PMID: 22880621 Review.
-
Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to know.J Am Acad Dermatol. 2012 Feb;66(2):317-22. doi: 10.1016/j.jaad.2011.08.034. J Am Acad Dermatol. 2012. PMID: 22243723 Review.
Cited by
-
Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience Gained.BioDrugs. 2018 Apr;32(2):129-135. doi: 10.1007/s40259-018-0262-9. BioDrugs. 2018. PMID: 29417431 Free PMC article. Review.
-
Comparing safety information of biosimilars with their originators: a cross-sectional analysis of European risk management plans.Br J Clin Pharmacol. 2018 Apr;84(4):738-763. doi: 10.1111/bcp.13454. Epub 2018 Jan 18. Br J Clin Pharmacol. 2018. PMID: 29164665 Free PMC article.
-
The biosimilar pathway in the USA: An analysis of the innovator company and biosimilar company perspectives and beyond.J Food Drug Anal. 2019 Jul;27(3):671-678. doi: 10.1016/j.jfda.2019.03.003. Epub 2019 Apr 30. J Food Drug Anal. 2019. PMID: 31324283 Free PMC article. Review.
-
Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars.BioDrugs. 2020 Apr;34(2):225-233. doi: 10.1007/s40259-019-00402-0. BioDrugs. 2020. PMID: 31925703 Free PMC article.
-
Satisfying QTPP of Erythropoietin Biosimilar by QbD through DoE-Derived Downstream Process Engineering.Pharmaceutics. 2023 Aug 4;15(8):2087. doi: 10.3390/pharmaceutics15082087. Pharmaceutics. 2023. PMID: 37631301 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources